Background {#Sec1}
==========

Primary Sjögren's syndrome (pSS) is a chronic autoimmune disease characterized by lymphocytic infiltration of the exocrine glands, including salivary and lachrymal glands, leading to qualitatively altered and diminished or absent glandular secretion. pSS is also characterized by marked B-lymphocyte hyperreactivity supported by hypergammaglobulinemia associated with the increase of a variety of serum autoantibodies \[[@CR1]\]. The characteristic involvement of salivary and lachrymal glands, clinically evidenced by dry mouth (xerostomia) and/or dry eyes (xerophthalmia), makes pSS an interesting application field for salivary proteomic analysis. Saliva and tears are easy and noninvasive biological fluids to collect and can mirror local and systemic pathological changes of the disease \[[@CR2]--[@CR4]\]. In previous studies on the salivary proteome in patients with pSS, researchers identified a number of proteins as possible pSS biomarkers. Some of these biomarkers showed significantly different levels from those of healthy subjects, whereas other biomarkers were detected exclusively in the saliva of patients with pSS \[[@CR3]--[@CR6]\]. In general, proteins of acinar origin were reduced in patients with pSS, whereas acute inflammatory phase proteins were increased in subjects with pSS, compared with those of healthy subjects.

Recently, β-thymosins (Tβs), a versatile family of small peptides with interesting intra- and extracellular activities that include cardiac protection, angiogenesis, stimulation of wound healing, and hair growth \[[@CR7]--[@CR16]\], was identified in human saliva and in tears \[[@CR17], [@CR18]\]. Tβs play pivotal roles in the cell cytoskeletal system, acting as G-actin-sequestering molecules, suggesting that their release by damaged cells might play a role in tissue repair, such as in damaged cornea \[[@CR19]\]. In particular, Tβ~4~, the most abundant Tβ in human tissues \[[@CR7], [@CR8]\], plays an important role in suppressing the production of interleukin-8 following stimulation by tumor necrosis factor-α, acting as an antimicrobial, anti-inflammatory, and antiapoptotic factor on gingival fibroblasts \[[@CR20]\]. Moreover, our group recently reported that Tβs are probably involved in the development of the oral cavity and its annexes \[[@CR21]\]. Another member of the Tβ family, Tβ~10~, is usually detectable at concentrations about five- to tenfold lower than Tβ~4~ in human tissues, but it has been reported to be overexpressed in human carcinogenesis \[[@CR22]\] and in fetal tissues, including the developing human brain \[[@CR23]\]. Involvement of Tβ~10~ in the development of the oral cavity, and in particular tooth germ development and tooth root formation, was reported recently in a mice study \[[@CR24]\]. In addition, our group reported strong expression of Tβ~10~ in the human salivary glands during development \[[@CR21]\]. Tβ~4~ sulfoxide was reported to have anti-inflammatory properties \[[@CR25]\], being overexpressed in the presence of oxidative stress, due to its potential scavenger properties \[[@CR26]\].

Because, to the best of our knowledge, no data had previously been reported on the presence of Tβ~4~, Tβ~4~ sulfoxide, and Tβ~10~ in human saliva of patients with Sjögren's syndrome (SS), the aim of this study was to investigate the presence and levels of salivary Tβs and the immunoreactivity of these peptides in minor salivary glands in a cohort of patients with SS and in patients with other autoimmune diseases, with and without sicca syndrome (ss), to better understand the possible role of these peptides in patients with pSS as well as patients with ss and other autoimmune diseases.

Methods {#Sec2}
=======

Patients and control subjects {#Sec3}
-----------------------------

All female patients were enrolled at the rheumatology clinic at the Catholic University of Rome, and the study was approved by the Catholic University Ethics Committee in Rome. After we obtained signed informed consent, we collected saliva specimens from nine patients with pSS according to previous and revised criteria for the disease \[[@CR27], [@CR28]\]. Patients with pSS had a mean age of 63.0 ± 11.2 years and a mean disease duration of 12.0 ± 7.1 years (Table [1](#Tab1){ref-type="table"}).Table 1Demographic and clinical characteristics of the patients and healthy control subjects enrolled in the studypSS (*n* = 9)ss/SSc (*n* = 7)ss/SLE (*n* = 7)ss/RA (*n* = 7)SSc (*n* = 7)SLE (*n* = 7)RA (*n* = 7)HC (*n* = 10)Age, years, mean ± SD55.8 ± 1363 ± 1151 ± 1661 ± 860.2 ± 748. ± 1064.1. ± 956.6 ± 12.5Disease duration, years, mean ± SD7.9 ± 4.212 ± 712 ± 910 ± 710.4 ± 811 ± 89.4 ± 8N/AAnti-Ro/SSA- and/or anti-La/SSB-positive, *n*90000000ANA-positive, *n*67717720RF-positive, *n*50060040Focus score ≥1, *n*6000N/AN/AN/A0UWS \<1.5 ml/15 minutes, *n*97770000Schirmer test result \<5 mm/5 minutes, *n*97770000Xerostomia, *n*97770000Xerophthalmia, *n*97770000*Abbreviation: pSS* Primary Sjögren's syndrome, *ss* Sicca syndrome, *SSc* Systemic sclerosis, *SLE* Systemic lupus erythematosus, *RA* Rheumatoid arthritis, *HC* Healthy control subjects, *UWS* Unstimulated whole saliva, *ANA* Antinuclear antibodies, *RF* Rheumatoid factor, *N/A* Not applicable

As control subjects, we considered three age-matched groups:Ten healthy subjects who had no signs or symptoms of ss and who were antinuclear autoantibody-negative, anti-extractable nuclear antigen autoantibody-negative, and rheumatoid factor autoantibody-negativeTwenty-one patients with ss associated with systemic sclerosis (SSc) (seven patients), with systemic lupus erythematosus (SLE) (seven patients), and with rheumatoid arthritis (RA) (seven patients); all of these patients complained of xerostomia and xerophthalmia, had a Schirmer test result \<5 mm in 5 minutes, and had unstimulated whole saliva flow \<1.5 ml in 15 minutes \[[@CR27]\], and none of them had anti-Ro/SSA or anti-La/SSB autoantibodies and lymphocytic infiltration of the salivary glandsSeven patients with SSc, seven with SLE, and seven with RA without symptoms or signs of ss

All patients were diagnosed according to the revised international classification criteria for SSc, SLE, and RA \[[@CR29]--[@CR31]\]. The disease durations were comparable in the different patient study groups (Table [1](#Tab1){ref-type="table"}).

In patients with pSS and with ss associated with SSc, SLE, or RA, saliva specimens were also collected after 30 minutes, 60 minutes, and 24 h from 5-mg pilocarpine intake. Patients with pSS and SLE were receiving antimalarial agents and a stable dose of prednisone \<7.5 mg/day. Patients with RA were treated with methotrexate 10--15 mg/week. Patients with SSc were treated with iloprost, calcium channel blockers, and acetylsalicylic acid.

Collection and preparation of saliva samples {#Sec4}
--------------------------------------------

Whole saliva was collected with a very soft plastic aspirator between 2:00 PM and 4:00 PM to reduce variations in concentrations associated with circadian rhythms of secretion. Samples were collected at least 30 minutes after any food or beverage had been consumed and teeth had been cleaned. A total of 0.5 ml of saliva was collected from each subject. Immediately after collection, samples were placed in an ice bath, and 0.5 ml of an acidic solution (0.2 % trifluoroacetic acid \[TFA\]) was added at a 1:1 ratio (vol/vol). The solution was then centrifuged at 8000 × *g* for 5 minutes at 4 °C. The supernatant was removed, and the precipitate was discarded. The supernatant was immediately analyzed by high-performance liquid chromatography (HPLC) in conjunction with mass spectrometry (MS) using a spectrometer equipped with an electrospray ionization (ESI) source. HPLC-ESI-MS was performed within 30 minutes of collection of the saliva sample.

HPLC-ESI-MS analysis of salivary proteins {#Sec5}
-----------------------------------------

The HPLC-ESI-MS apparatus used was a Surveyor HPLC instrument (Thermo Fisher Scientific, Waltham, MA, USA) connected by a T splitter to a photodiode array detector and an LCQ Deca XP Plus mass spectrometer (Thermo Fisher Scientific). The chromatography column was a Vydac C8 column (Thermo Fisher Scientific) with a 5-μm particle diameter (column dimensions of 150 mm in length × 2.1-mm inner dimension). The following solutions were used for reversed-phase chromatography: Eluent A consisted of 0.056 % (vol/vol) aqueous TFA, and eluent B consisted of 0.050 % (vol/vol) TFA in acetonitrile/water 80/20 (vol/vol). The gradient applied was linear, from 0 % to 55 % of eluent B over 40 minutes, at a flow rate of 0.30 ml/minute. The T splitter addressed a flow rate of approximately 0.20 ml/minute toward the diode array detector and a flow rate of about 0.10 ml/minute toward the ESI source. The diode array detector was set at two wavelengths: 214 nm and 276 nm. Mass spectra were collected every 3 milliseconds in the positive ion mode. The MS spray voltage was 4.50 kV, and the capillary temperature was 250 °C. All common chemicals and reagents for the HPLC-MS analysis were of analytical grade and were purchased from Merck (Darmstadt, Germany) and Baker (Mallinckrodt Baker B.V., Deventer, the Netherlands). Deconvolution of the average ESI mass spectra was automatically performed by using MagTran 1.0 software (Amgen, Thousand Oaks, CA, USA) \[[@CR32]\]. Experimental mass values obtained from the analysis were compared with theoretical values available from the Swiss-Prot \[[@CR33]\] and EMBL \[[@CR34]\] databases. The relative abundance of the different salivary Tβs was determined by using the extracted-ion current (XIC) strategy. The XIC procedure for each protein was based on the extraction from the total ion current profile of three mass-to-charge (*m/z*) values selected for each protein among the most relevant, provided that these did not overlap with the *m/z* values of nearly eluting proteins. Taking into account that constant analytical conditions were used for each sample, the numerical value corresponding to the integrated XIC peak area was used for the estimations of the relative abundance of peptides/proteins and for the statistical analysis. The calculated areas are all referred to a saliva volume of 17 μl. Standards of Tβ~4~ and Tβ~10~ were purchased from Bachem (Bubendorf, Switzerland), and the standard of Tβ~4~ sulfoxide was obtained, as previously described, by oxidation of Tβ~4~ \[[@CR17]\].

Immunohistochemical analyses {#Sec6}
----------------------------

Samples of minor salivary glands were obtained through an incisional biopsy taken (after inducing local anesthesia) at the endobuccal border of the lower lip from six female patients affected by SS, three with ss/SSc, three with ss/SLE, and three with ss/RA, as well as from three healthy control subjects. In patients with SS, minor salivary gland samples had an average focus score \>1 according to the Chisholm-Mason scoring system. The focus score was calculated as the number of lymphocytic foci multiplied by 4-mm^2^ surface in at least four informative lobules, and a focus was defined as a cluster of at least 50 lymphocytes \[[@CR35]\].

All tissue samples were fixed in 10 % formalin, routinely processed, and embedded in paraffin. Immunohistochemistry was performed on 4-μm-thick sections using a labeled streptavidin-biotin complex system (LSAB2; Dako, Glostrup, Denmark) in an autostainer (Dako Cytomation, Carpinteria, CA, USA). Briefly, paraffin sections were deparaffinized and rehydrated, and endogenous peroxidase activity was quenched by 0.3 % hydrogen peroxide in methanol (30 minutes). Heat-induced antigen retrieval was carried out by steaming unstained sections in the target retrieval solution (pH 6.1; Dako) for 30 minutes. Serial sections were then incubated with 10 % normal goat serum in PBS for 60 minutes to block nonspecific binding, followed by incubation with a polyclonal anti-Tβ~4~ antibody (Bachem-Peninsula Laboratories, San Carlos, CA, USA) and with a monoclonal anti-Tβ~10~ antibody (Bachem-Peninsula Laboratories), diluted 1:600 and 1:500, respectively, in the blocking solution. Slides were then extensively washed with PBS containing 0.01 % Triton X-100 and incubated with a secondary reagent (EnVision kit; Dako) according to the manufacturer's instructions. Diaminobenzidine was used as a chromogen. After additional washes, color was developed using the AEC reagent (Dako), and sections were counterstained with Mayer's hematoxylin and mounted. Sections of reactive lymph nodes with Tβ~4~- and Tβ~10~-immunoreactive histiocytes were used as a positive control. As a negative control, the same procedure was applied with minor salivary gland sections, omitting the primary antibody.

Statistical analyses {#Sec7}
--------------------

Statistical analysis was performed with SPSS version 13.0 software (SPSS, Chicago, IL, USA). Categorical and quantitative variables were described as numbers and percentages, respectively, as well as the mean ± SD. In the eight different patient subgroups considered, the analysis was performed by considering the differences either in the frequency of every single protein or in its levels. The Mann-Whitney *U* test and Wilcoxon's matched-pairs signed-rank test were used to compare continuous variables. Categorical variables were analyzed using the chi-square test or Fisher's exact test, depending on sample size restrictions. A *p* value ≤0.05 was considered significant.

Results {#Sec8}
=======

Proteomic analysis of salivary Tβ~4~ and Tβ~10~ {#Sec9}
-----------------------------------------------

Tβ~4~ was detected in the saliva of the vast majority of patients affected by SICCA (pSS + ss), with percentages ranging from 85.7 % in the subjects with ss/SSc and those with ss/RA to 88.9 % in subjects affected by pSS and to 100 % in patients with ss/SLE. Tβ~4~ was detected in the saliva of 90 % of healthy subjects. Salivary Tβ~4~ was detected at lower percentages in patients with autoimmune diseases and without ss, ranging from 28.6 % in the SLE group to 42.8 % in patients with SSc and those with RA (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}).Table 2Thymosin β levels and frequency detection in different subgroupsTβ~4~Tβ~10~Tβ~4~ sulfoxidepSS3.5 ± 3.1 (*n* = 8)^a^0.2 ± 0.3 (*n* = 6)1.6 ± 3.3 (*n* = 4)^a^ss/SSc0.7 ± 1.0 (*n* = 6)^b^0.03 ± 0.05 (*n* = 3)^a,b^0.2 ± 0.4 (*n* = 3)ss/SLE0.6 ± 0.4 (*n* = 7)^b^N/A (*n* = 1)N/A (*n* = 1)ss/RA1.2 ± 1.1 (*n* = 6)N/A (*n* = 1)N/A (*n* = 1)SSc0.3 ± 0.6 (*n* = 3)^b^N/A (*n* = 0)^b^N/A (*n* = 0)SLE0.1 ± 0.2 (*n* = 2)^a,b^N/A (*n* = 0)^b^N/A (*n* = 0)RA0.2 ± 0.4 (*n* = 3)N/A (*n* = 0)^b^N/A (*n* = 0)HC0.8 ± 0.6 (*n* = 9)N/A (*n* = 0)^b^N/A (*n* = 0)*Abbreviations: pSS* Primary Sjögren's syndrome, *ss* Sicca syndrome, *SSc* Systemic sclerosis, *SLE* Systemic lupus erythematosus, *RA* Rheumatoid arthritis, *HC* Healthy control subjects, *N/A* Not applicable to the comparison between levels (as continuous variable) because of too few patients with detectable thymosins in the considered groupValues are the mean ± SD protein levels in the extracted ion current area (×10^8^). Values in parentheses are the number of subjects in whom the protein was identified^a^ *p* ≤ 0.05 vs HC either in levels of thymosin β and/or in its presence^b^ *p* ≤ 0.05 vs pSS either in thymosin β levels and/or in its presence Table 3Immunohistochemical and salivary detection of thymosin β in different subgroupsGroupTβ~4~ IHCTβ~4~ salivaTβ~4~ sulfoxide salivaTβ~10~ salivaTβ~10~ IHCpSS−88.9 %44.4 %66.7 %+++ss/SSc+85.7 %42.9 %42.8 %+ss/SLE+100 %14.3 %14.3 %+ss/RA−85.7 %14.3 %14.3 %+++HC−90 %0 %0 %−*Abbreviations: pSS* Primary Sjögren's syndrome, *ss* Sicca syndrome, *SSc* Systemic sclerosis, *SLE* Systemic lupus erythematosus, *RA* Rheumatoid arthritis, *HC* Healthy control subjects, *IHC* Immunohistochemical staining, − Negative staining, + Positive staining

Tβ~4~ sulfoxide was found in a lower percentage of patients affected by SICCA (pSS + ss), ranging from 14.3 % in the ss/RA and ss/SLE groups to 42.9 % in the ss/SSc patients and up to 44.4 % in the pSS group. No healthy subjects showed the presence of Tβ~4~ sulfoxide in saliva (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}).

Marked differences were observed among the different subgroups of patients affected by SICCA (pSS + ss) regarding the occurrence of Tβ~10~ in saliva. The percentage of salivary Tβ~10~ ranged from 14.3 % in the ss/SLE and ss/RA groups to 42.8 % in the patients with ss/SSc and up to 66.7 % in subjects affected by pSS.

No healthy subjects showed the presence of Tβ~10~ in saliva. In patients affected by SSc, RA, and SLE but without ss, both Tβ~4~ sulfoxide and Tβ~10~ were constantly absent in saliva (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}).

When quantitative analyses of the salivary levels of thymosins were carried out, the highest levels of Tβ~4~, Tβ~10~, and Tβ~4~ sulfoxide were found in patients with pSS (3.5 ± 3.1 × 10^8^, 0.2 ± 0.3 × 10^8^, and 1.6 ± 3.3 × 10^8^, respectively) (Table [2](#Tab2){ref-type="table"}). Tβ~4~ levels in subjects with pSS (3.5 ± 3.1 × 10^8^) were significantly higher than in the HC group (0.8 ± 0.6 × 10^8^) (*p* \< 0.05).

All patients with SS and all patients with ss were treated with a single oral dose of 5 mg of pilocarpine, and their thymosin levels were evaluated before and after treatment. No differences were found in Tβ~4~, Tβ~10~, and Tβ~4~ sulfoxide levels before and after the drug intake in patients with SICCA (pSS and ss).

Histology and immunohistochemistry {#Sec10}
----------------------------------

The histological picture of minor salivary glands in patients affected by pSS was characterized by the presence of an inflammatory infiltrate represented mainly by lymphocytes, with a focus score \>1 in all cases in which histology was performed. On the contrary, no inflammatory infiltrate was detected in minor salivary glands taken from patients in the other groups.

At the time of immunohistochemistry, Tβ~4~ and Tβ~10~ were not detectable in the minor salivary glands of the healthy subjects. Marked differences were detected regarding the expression of Tβ~4~ and Tβ~10~ in patients affected by pSS, whereas the latter was characterized by high immunostaining, appearing as cytoplasmic granular deposits in acinar serous cells. On the contrary, immunoreactivity for Tβ~4~ was completely absent in acinar as well as ductal cells (Fig. [1](#Fig1){ref-type="fig"}). A similar immunohistochemical staining (IHC) pattern was detected in patients affected by ss/RA, with minor salivary glands being characterized by a strong, diffuse, homogeneous reactivity for Tβ~10~ in ductal cells and absence of any significant immunostaining for Tβ~4~. A different IHC pattern, characterized by immunostaining for both Tβ~4~ and Tβ~10~ in acinar cells, was observed in patients with ss/SSc or ss/SLE.Fig. 1Thymosin β~4~ (Tβ~4~) and Tβ~10~ immunostaining in patients with primary Sjögren's syndrome (pSS) and sicca symptoms and other autoimmune diseases. **a** Tβ~10~ in patients with pSS: immunoreactive granules in acinar cells. **b** Tβ~4~ in patients with pSS: No immunoreactivity is detected in acinar and ductal cells. **c** Tβ~10~ in patients with sicca syndrome and rheumatoid arthritis (ss/RA): Strong immunostaining is observed in ductal cells. **d** Tβ~4~ in patients with ss/RA: No reactivity is observed in either acinar or in ductal cells. **e** Tβ~4~ in patients with systemic sclerosis and sicca syndrome (ss/SSc): Granular immunostaining is observed in acinar cells. **f** Tβ~10~ in patients with ss/SSc: Immunoreactivity is observed mainly in serous acinar cells

Discussion {#Sec11}
==========

In SS, the proteomic analysis of saliva appears to be a very useful way to assess how the autoimmune disease affects the exocrine function of salivary glands. It is an important tool for identifying biomarkers and posttranslational modifications, as well as for identifying and quantifying peptides, proteins, and neoantigens. A number of proteins have been indicated as pSS biomarkers, showing two- to threefold up- or downregulation at significantly different levels compared with healthy subjects or having an exclusive presence in SS saliva. Proteins of acinar origin (i.e., α-amylase, carbonic anhydrase VI, proline-rich proteins, prolactin-inducible protein precursor) were reduced in patients with pSS, while inflammatory phase proteins, protease inhibitors, and antimicrobial peptides (i.e., lactoferrin, β~2~-microglobulin, immunoglobulin κ-light chain, calgranulin B, lipocalin 1 precursor, phosphatidylethanolamine binding protein, and defensins) were increased, compared with those in healthy subjects \[[@CR3]--[@CR6]\].

Recently, Tβs, which are ubiquitous peptides with interesting intra- and extracellular functions, were identified in human saliva \[[@CR17], [@CR18]\]. Their roles in cytoskeleton rearrangement, anti-inflammatory response, stimulation of wound healing, re-epithelialization of damaged cornea, cardiac protection, and angiogenesis \[[@CR9]--[@CR12]\] support a possible release of Tβ in the saliva of patients with oral mucosal damage, such as in pSS, and therefore a possible involvement of these peptides in the pathogenesis of pSS.

Tβ~4~ is the most abundant Tβ, representing about 70--80 % of the total Tβ content, and it is a multifunctional protein that has pleotropic activities important in cell survival and repair. It is present in all cells except red blood cells, as well as in all studied body fluid (saliva, tears, blood, plasma, wound fluid) \[[@CR7]--[@CR10]\]. Because Tβ~4~ lacks a secretion signal, it is speculated that its presence in body fluids is due to damaged cells. It is localized both in the cytoplasm and in the cell nucleus. Tβ~4~ has been shown to promote dermal and ocular repair \[[@CR19]\], in part because of its potent chemotactic activity. It promotes the migration of various other cells, including stem cells from the hair follicles, resulting in increased hair growth \[[@CR10]\]; tumor cells, resulting in increased metastasis; and embryonic progenitor cells from cardiac tissue, resulting in the formation of new vessels \[[@CR11]--[@CR13]\]. Tβ~4~ has been detected in human whole saliva and in tears by immunological techniques \[[@CR18]\], and recent studies by our group evidenced that, in the oral cavity, a main contribution derives from crevicular fluid \[[@CR17]\], where, as demonstrated by Reti and coworkers \[[@CR20]\], Tβ~4~ plays an important role in suppressing the production of interleukin-8 following stimulation by tumor necrosis factor-α and acts on the whole saliva as an antimicrobial, anti-inflammatory, and antiapoptotic peptide on gingival fibroblasts. The ability of Tβ~4~ to block apoptosis and downregulate inflammatory cytokines may explain its anti-inflammatory activity. Tβ~4~ also increases oxidative enzymes and protects cells and tissues from oxidative damage. In different body fluids, the oxidation product of Tβ~4~ at the methionine-6 residue, Tβ~4~ sulfoxide was also detectable. Tβ~4~ sulfoxide is generated by monocytes in the presence of glucocorticoids, and, like Tβ~4~, it seems to have anti-inflammatory properties \[[@CR25], [@CR26]\].

Tβ~4~ frequently coexists with a second member of the Tβ family: Tβ~10~ \[[@CR13]\]. Tβ~10~ concentration is usually about 20 times lower than Tβ~4~ in normal tissues, but the Tβ~10~/Tβ~4~ ratio seems to increase in preneoplastic and neoplastic tissues and in activated lymphocytes \[[@CR13]\].

Whereas Tβ~4~ is a potent enhancer of angiogenesis, Tβ~10~ inhibits it, and changes in the ratio of the two peptides can exert either a positive or negative control \[[@CR10]\]. Tβ~4~ can upregulate the expression of hepatocyte growth factor and downregulate the expression of platelet-derived growth factor-β receptor in a model of liver fibrosis, suggesting an antifibrotic potential of Tβ~4~ \[[@CR36], [@CR37]\].

In this study, the presence and the levels of Tβ~4~, Tβ~4~ sulfoxide, and Tβ~10~ were determined both in saliva by a proteomic approach and in salivary glands by immunohistochemistry. This integrated approach allowed us to compare Tβ~4~ and Tβ~10~ expression in saliva and in salivary glands of healthy subjects, patients with pSS, and patients with ss and other autoimmune diseases. Tβ~4~ was present in the saliva of the vast majority of patients complaining of ss symptoms and in healthy control subjects, but its levels were significantly higher in subjects affected by SS than in the other subgroups.

The high levels of Tβ~4~ found in the saliva of patients with SS contrasted with the absence of reactivity for the peptide in salivary glands observed by immunohistochemistry. This finding suggests that acinar cells of salivary glands constantly exposed to inflammatory damage of SS might release high amounts of Tβ~4~ in the saliva, where it would exert a cytoprotective effect in tissue repair and in the anti-inflammatory response, as previously shown in the damaged cornea \[[@CR19]\]. Alternatively, the increased apoptosis of epithelial cells that characterize pSS can release the peptide, with the new and regenerating epithelial cells not producing enough peptide to be detected by IHC \[[@CR38]\]. This is supported indirectly by the observation that Tβ~10~ is expressed more frequently than Tβ~4~ in IHC and that in fact Tβ~10~ is involved in apoptosis mechanisms \[[@CR39]\].

Tβ~10~ and Tβ~4~ sulfoxide were selectively detectable in patients with SICCA (ss + pSS), as compared with none of the patients without associated ss or the healthy control subjects. Our data suggest that these two isoforms of Tβ could be salivary biomarkers of SICCA. The highest levels of Tβ~4~ sulfoxide and Tβ~10~ were found in patients with pSS. The increased levels of Tβ~4~ sulfoxide in pSS saliva could mirror the higher oxidative stress status of the oral cavity related to a characteristic inflammatory microenvironment due to the immunological destruction of the salivary glands typical of pSS. Indeed, the release of an increased amount of Tβ~4~ sulfoxide could represent a scavenger mechanism able to reduce the negative effects of oxidative stress on salivary proteins and enzymes, along with a cytoprotective effect, in both forms.

Tβ~10~ has a similar expression pattern of Tβ~4~ sulfoxide in pSS and ss saliva, and its presence may be due to a passive release from damaged cells, such as Tβ~4~. The increased amount of Tβ~10~ in pSS saliva could be related to the activated lymphocytes present in salivary gland infiltrates.

It has been shown that thymosins prevent scarring and fibrosis in many animal models of human pathologies through their potent regenerative and antifibrotic effect in reducing inflammation and in modulating oxidative damage. In this scenario, our data suggest a role of thymosins in pSS and in patients with ss related to other autoimmune diseases, supporting a rationale for expecting thymosins' therapeutic effect in clinical practice in patients with ss symptoms, as well as what has already been reported in lung damage \[[@CR40], [@CR41]\], eye injury \[[@CR19]\], and wound healing of the palatal mucosa \[[@CR42]\].

Conclusions {#Sec12}
===========

Proteomic analysis of the expression of Tβ~4~, Tβ~4~ sulfoxide, and Tβ~10~ mirrors the different oral microenvironment of patients with pSS and with autoimmune diseases who complain of ss. Thymosins may potentially be used as biomarkers in patients with pSS and patients with ss, and IHC analysis helped us to hypothesize their possible role. Functional studies at the epithelial cell level are necessary to further elucidate their role.
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